Compare Quest Diagnostics Inc (DGX) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs MobilEye Global Inc — how do they compare? Quest Diagnostics Inc trades at $236.79 (market cap $26.21B), while MobilEye Global Inc trades at $8.74 (market cap $7.54B). The key difference: Quest Diagnostics Inc is far larger — about 3.5× MobilEye Global Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals.
| DGX | MBLY | |
|---|---|---|
Market Cap | $26.21B | $7.54B |
Sector | Health | Technology |
52-Week High | $238.50 | $15.54 |
52-Week Low | $173.49 | $6.56 |
Enterprise Value | $31.97B | $6.10B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Mobileye Global Inc. (MBLY) trades at $8.81, up 0.69% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings beats, driven by an R&D grant, though it remains unprofitable with a net income margin of -201.49%. Recent news highlights CEO transition plans and a new supply deal with Stellantis, while analyst consensus is bullish with a $11.40 price target.
The outlook is mixed: raised 2026 guidance and strategic partnerships offer growth potential in autonomous driving, but persistent losses, leadership changes, and high valuation multiples pose significant risks. Investors should weigh the company's technological positioning against its current financial health and execution challenges in a competitive market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
